Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Related Citations for PubMed (Select 18845949)

1.

Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa.

Black V, Hoffman RM, Sugar CA, Menon P, Venter F, Currier JS, Rees H.

J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):276-81. doi: 10.1097/QAI.0b013e318189a769.

2.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

PMID:
23924192
3.

Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.

Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L.

Trop Med Int Health. 2010 Jul;15(7):825-32. doi: 10.1111/j.1365-3156.2010.02538.x. Epub 2010 May 18.

4.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

5.

Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa.

Hoffman RM, Black V, Technau K, van der Merwe KJ, Currier J, Coovadia A, Chersich M.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):35-41. doi: 10.1097/QAI.0b013e3181cf9979.

6.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M.

N Engl J Med. 2010 Jun 17;362(24):2282-94. doi: 10.1056/NEJMoa0907736.

7.

Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.

AIDS. 2008 Sep 12;22(14):1815-20. doi: 10.1097/QAD.0b013e32830b8ab9.

PMID:
18753864
8.

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi L.

HIV Med. 2006 Jul;7(5):338-44.

PMID:
16945080
9.

The impact of revised PMTCT guidelines: a view from a public sector ARV clinic in Cape Town, South Africa.

Van Schalkwyk M, Andersson MI, Zeier MD, La Grange M, Taljaard JJ, Theron GB.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):234-8. doi: 10.1097/QAI.0b013e31828bb721.

10.

Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission.

Short CE, Douglas M, Smith JH, Taylor GP.

HIV Med. 2014 Apr;15(4):233-8. doi: 10.1111/hiv.12083. Epub 2013 Sep 11.

PMID:
24025074
11.

Optimal time on HAART for prevention of mother-to-child transmission of HIV.

Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, Chi BH, Stringer JS, Stringer EM.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):224-8. doi: 10.1097/QAI.0b013e318229147e.

12.

[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].

Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME.

Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5. Dutch.

PMID:
15553999
13.

Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.

Tsague L, Tsiouris FO, Carter RJ, Mugisha V, Tene G, Nyankesha E, Koblavi-Deme S, Mugwaneza P, Kayirangwa E, Sahabo R, Abrams EJ.

BMC Public Health. 2010 Dec 6;10:753. doi: 10.1186/1471-2458-10-753.

14.

Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.

Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, Hughes MD, Tuomala R.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):27-34. doi: 10.1097/QAI.0b013e3181caea89.

15.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.

J Infect Dis. 2009 Nov 15;200(10):1490-7. doi: 10.1086/644598.

16.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
17.

High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.

Powis KM, McElrath TF, Hughes MD, Ogwu A, Souda S, Datwyler SA, von Widenfelt E, Moyo S, Nádas M, Makhema J, Machakaire E, Lockman S, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):517-24. doi: 10.1097/QAI.0b013e318286d77e.

18.

Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.

Johnson N, Palmer P, Samuels LA, Morgan O, Onyonyor A, Anderson M, Moore J, Billings C, Harvey KM, Mullings A, McDonald D, Alexander G, Smikle MF, Williams EW, Davis D, Christie CD.

West Indian Med J. 2008 Jun;57(3):216-22.

PMID:
19583119
19.

When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?

Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, Anderson J, Hawkins DA, Taylor GP, de Ruiter A; London HIV Perinatal Research Group.

AIDS. 2012 Jun 1;26(9):1095-103. doi: 10.1097/QAD.0b013e3283536a6c.

PMID:
22441248
20.

Reduction of maternal mortality with highly active antiretroviral therapy in a large cohort of HIV-infected pregnant women in Malawi and Mozambique.

Liotta G, Mancinelli S, Nielsen-Saines K, Gennaro E, Scarcella P, Magid NA, Germano P, Jere H, Guidotti G, Buonomo E, Ciccacci F, Palombi L, Marazzi MC.

PLoS One. 2013 Aug 19;8(8):e71653. doi: 10.1371/journal.pone.0071653. eCollection 2013. Erratum in: PLoS One. 2013;8(8). doi: 10.1371/annotation/9ab4708e-650e-411a-b72f-bb85e0845469. Gennaro, E [corrected to Gennaro, Elisabetta]; Guidotti, Gianni [corrected to Guidotti, Giovanni].

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk